Intravitreal Dexamethasone Implant for Postoperative Macular Oedema Secondary to Vitrectomy for Epiretinal Membrane and Retinal Detachment: A Systematic Review and Meta‐Analysis
Open Access
- 1 January 2021
- journal article
- review article
- Published by Wiley in Journal of Ophthalmology
- Vol. 2021 (1)
Abstract
Purpose . To evaluate the efficacy of intravitreal dexamethasone implant (DEX) for the treatment of macular oedema secondary to vitrectomy for epiretinal membrane (ERM) and retinal detachment (RD) by conducting a systematic review with meta‐analysis of published studies. Methods . Studies reporting clinical outcomes of DEX use for the treatment of macular oedema secondary to ERM and RD vitrectomy were searched on PubMed and Embase databases. The primary outcome was best‐corrected visual acuity (BCVA) change between baseline and post‐DEX treatment, reported as mean difference (MD) with 95% confidence interval (CI). Mean central macular thickness (CMT) change was assessed as a secondary outcome. Postimplant adverse events, including intraocular pressure rise and cataract development, were reported as well. Results . Five uncontrolled studies, 1 nonrandomized controlled study, and 1 randomized controlled study were included, with a total of 5 cohorts and 3 cohorts in the ERM group and RD group, respectively. Considering the last available follow‐up, a significant improvement in postimplant BCVA was found in the overall population, irrespective of the indication for vitrectomy (MD = −0.28, 95% CI = −0.37, −0.20; p < 0.001), but with significant heterogeneity. In either group, mean BCVA significantly improved following the implant (in the ERM group, MD = −0.31, 95% CI = −0.40, −0.22; in the RD group, MD = −0.22, 95% CI = −0.41, −0.03), with no difference between the two groups ( p = 0.41). However, there was significant heterogeneity in both groups. Considering the last available follow‐up, a significant CMT reduction was found in the overall population, irrespective of the indication for vitrectomy (MD = −129.75, 95% CI = −157.49, −102.01; p < 0.001). In the ERM group, a significant CMT reduction was shown following DEX (MD = −133.41, 95% CI = −155.37, −111.45; p < 0.001), with no heterogeneity. In the RD group, mean CMT reduction was borderline significant (MD = −128.37, 95% CI = −253.57, −3.18; p = 0.040), with significant heterogeneity. No difference in CMT improvement was found between the two groups ( p = 0.94). Conclusion . This meta‐analysis showed that DEX yielded a significant improvement in visual and anatomical outcomes, even if limited by significant heterogeneity. Dexamethasone implant represents an effective treatment for postoperative macular oedema secondary to ERM and RD vitrectomy.Keywords
This publication has 31 references indexed in Scilit:
- Intravitreal Dexamethasone Implant for Cystoid Macular Edema and Inflammation after Scleral BucklingEuropean Journal of Ophthalmology, 2015
- Epiretinal Membrane and Cystoid Macular Edema after Retinal Detachment Repair with Small-Gauge Pars Plana VitrectomyEuropean Journal of Ophthalmology, 2015
- Management of pseudophakic cystoid macular edemaSurvey of Ophthalmology, 2015
- INTRAVITREAL DEXAMETHASONE IMPLANT FOR REFRACTORY MACULAR EDEMA SECONDARY TO VITRECTOMY FOR MACULAR PUCKERRetina, 2014
- Cystoid macular edema after pars plana vitrectomy for idiopathic epiretinal membraneGraefe's Archive for Clinical and Experimental Ophthalmology, 2014
- Pseudophakic Cystoid Macular EdemaOphthalmologica, 2011
- DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTSRetina, 2011
- Cataract Surgery Induces Retinal Pro-inflammatory Gene Expression and Protein SecretionInvestigative Ophthalmology & Visual Science, 2011
- ANATOMIC AND FUNCTIONAL OUTCOME AFTER 23-GAUGE VITRECTOMY, PEELING, AND INTRAVITREAL TRIAMCINOLONE FOR IDIOPATHIC MACULAR EPIRETINAL MEMBRANERetina, 2009
- Incidence of Postvitrectomy Macular Edema Using Optical Coherence TomographyOphthalmology, 2009